Bicara Therapeutics/$BCAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Ticker

$BCAX
Sector
Primary listing

Employees

55

BCAX Metrics

BasicAdvanced
$984M
-
-$2.35
-
-

Bulls say / Bears say

In a Phase 1/1b dose expansion for metastatic or advanced cSCC unresponsive to anti–PD-1 therapy, ficerafusp alfa achieved a 30.4% overall response rate and a median 7.0-month progression-free survival, outperforming historical results in this difficult population.
As of March 31, 2025, Bicara had $462.1 million in cash and cash equivalents, supporting operations into the first half of 2029 and reducing immediate financing risk.
Patient enrollment continues in FORTIFI-HN01, the pivotal Phase 2/3 trial of ficerafusp alfa with pembrolizumab in first-line recurrent/metastatic HNSCC, marking progress toward potential approval data.
Ficerafusp alfa is still in Phase 1/1b and pivotal Phase 2/3 trials with no approved products yet, which lengthens the path to commercialization and raises execution risk.
Bicara posted a net loss of $36.8 million in Q1 2025, up from $12.5 million a year ago, showing a high cash burn that could strain reserves before any product reaches approval.
In the Phase 1/1b cSCC group, 74% of patients had dermatitis acneiform and 30% experienced epistaxis, signaling potential side effect concerns that could hinder broader adoption.
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCAX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs